RXRX

3.17

0.00% 0.00

Handel nachbörslich: 3.13 -0.04 -1.26%

Recursion Pharmaceuticals Inc (RXRX)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt RXRX? Forum Prognose

Schlusskurs vom Vortag:

$3.17

Offen:

$3.215

24-Stunden-Volumen:

13.47M

Relative Volume:

0.68

Marktkapitalisierung:

$1.67B

Einnahmen:

$74.68M

Nettoeinkommen (Verlust:

$-644.76M

KGV:

-2.1377

EPS:

-1.4829

Netto-Cashflow:

$-380.44M

1W Leistung:

-4.52%

1M Leistung:

-15.92%

6M Leistung:

-31.53%

1J Leistung:

-51.45%

1-Tages-Spanne:

$3.11

$3.2853

1-Wochen-Bereich:

$3.08

$3.45

52-Wochen-Spanne:

$2.98

$7.18

Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile

Firmenname

Recursion Pharmaceuticals Inc

Sektor

Healthcare (1114)

Branche

Biotechnology (623)

Telefon

(385) 269-0203

Adresse

41S RIO GRANDE STREET, SALT LAKE CITY

Mitarbeiter

600

Twitter

Nächster Verdiensttermin

2024-11-06

Neueste SEC-Einreichungen

RXRX's Discussions on Twitter

Compare RXRX vs VRTX, REGN, ALNY, ARGX, INSM

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
RXRX Recursion Pharmaceuticals Inc	3.17	1.67B	74.68M	-644.76M	-380.44M	-1.4829
VRTX Vertex Pharmaceuticals Inc	454.97	113.96B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	749.47	78.41B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	328.70	40.85B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	697.05	42.05B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	148.31	29.99B	606.42M	-1.28B	-997.58M	-6.403

Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-12-17	Hochstufung	JP Morgan	Neutral → Overweight
2025-07-03	Fortgesetzt	Morgan Stanley	Equal-Weight
2023-05-22	Eingeleitet	Morgan Stanley	Equal-Weight
2023-03-16	Eingeleitet	Needham	Buy
2022-09-16	Eingeleitet	KeyBanc Capital Markets	Overweight
2022-04-18	Herabstufung	BofA Securities	Buy → Neutral
2022-03-04	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2021-09-21	Eingeleitet	Berenberg	Buy
2021-05-11	Eingeleitet	BofA Securities	Buy
2021-05-11	Eingeleitet	Goldman	Neutral
2021-05-11	Eingeleitet	JP Morgan	Neutral
2021-05-11	Eingeleitet	KeyBanc Capital Markets	Overweight
2021-05-11	Eingeleitet	SVB Leerink	Outperform

Alle ansehen

Recursion Pharmaceuticals Inc Aktie (RXRX) Neueste Nachrichten

05:08 AM

Recursion Pharmaceuticals Names New Chief Medical Officer - TipRanks

05:08 AM

04:53 AM

Recursion appoints Vicki Goodman as Chief Medical Officer; David Mauro to transition to advisor - TradingView

04:53 AM

08:44 AM

EXEL: Former Executive Joins Recursion Pharmaceuticals as New CM - GuruFocus

08:44 AM

08:00 AM

Recursion Announces Vicki Goodman, M.D., as Incoming Chief Medical Officer - marketscreener.com

08:00 AM

Mar 24, 2026

Assessing Recursion Pharmaceuticals (RXRX) Valuation After Prolonged Share Price Weakness - Sahm

Mar 24, 2026

Recursion Pharmaceuticals Stock (RXRX) Opinions on Roche's AI Drug Development Commitment - Quiver Quantitative

Mar 24, 2026

Mar 23, 2026

Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo

Mar 23, 2026

Mar 22, 2026

Prediction: The "Trough of Disillusionment" Will Create the Best Buying Opportunity for Artificial Intelligence (AI) Stocks in 2026 - The Motley Fool

Mar 22, 2026

Recursion Pharmaceuticals Details AI-Driven Drug Pipeline, Sanofi/Roche Milestones, Runway to 2028 - MarketBeat

Mar 22, 2026

Mar 19, 2026

Recursion’s Khan: AI will be judged by the medicines it makes - BioCentury

Mar 19, 2026

Recursion Pharmaceuticals (RXRX) Advances While Market Declines: Some Information for Investors - Yahoo Finance

Mar 19, 2026

Mar 18, 2026

What makes Recursion Pharmaceuticals (RXRX) so attractive - MSN

Mar 18, 2026

Ben Taylor Sells 7,956 Shares of Recursion Pharmaceuticals (NASDAQ:RXRX) Stock - MarketBeat

Mar 18, 2026

Recursion Pharma CFO Taylor sells $26970 in shares - Investing.com

Mar 18, 2026

CFO of Recursion Pharmaceuticals (RXRX) sells 7,956 shares under 10b5-1 plan - Stock Titan

Mar 18, 2026

Recursion Pharmaceuticals sets post-hype agenda at LeerinkPartners healthcare event - Traders Union

Mar 18, 2026

BofA lowers PT on Recursion Pharmaceuticals (RXRX), keeps a hold rating - MSN

Mar 18, 2026

Mar 16, 2026

Jim Cramer on Recursion Pharmaceuticals: “It’s a let down, big let down” - MSN

Mar 16, 2026

Mar 15, 2026

Why Recursion Pharmaceuticals, Inc. (RXRX)'s upside case hasn't fully convinced yet - MSN

Mar 15, 2026

Mar 14, 2026

RXRX SEC FilingsRecursion Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan

Mar 14, 2026

Is Recursion Pharmaceuticals, Inc. (RXRX) the best fundamentally strong penny stock to buy? - MSN

Mar 14, 2026

Costco, AMD, Recursion Pharmaceuticals, Cipher Mining And Snowflake: Why These 5 Stocks Are On Investors' Radars Today - AOL.com

Mar 14, 2026

Mar 13, 2026

Measuring the AI Bubble - Pharmaceutical Executive

Mar 13, 2026

Jim Cramer on Recursion Pharmaceuticals: “It’s a Let Down, Big Let Down” - Insider Monkey

Mar 13, 2026

A Look At Recursion Pharmaceuticals (RXRX) Valuation After Q4 Beat And AI Clinical Progress - Sahm

Mar 13, 2026

Mar 12, 2026

PARG inhibitors disclosed in Recursion Pharmaceuticals patent - BioWorld MedTech

Mar 12, 2026

Mar 11, 2026

Recursion Pharmaceuticals and Applied Digital shares fall after Nvidia exits stakes - MSN

Mar 11, 2026

Needham Retains Buy Rating on Recursion Pharmaceuticals, Maintains PT at $8 - MSN

Mar 11, 2026

Recursion Pharmaceuticals (NASDAQ:RXRX) CEO Sells $94,798.30 in Stock - MarketBeat

Mar 11, 2026

Recursion (NASDAQ: RXRX) director converts 20K Class B, gifts 20K A - Stock Titan

Mar 11, 2026

Jim Cramer on Recursion: “It is so low that it comes in under the category of speculative” - MSN

Mar 11, 2026

Mar 10, 2026

Recursion Pharmaceuticals (RXRX) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance

Mar 10, 2026

Is Recursion Pharmaceuticals (RXRX) Pricing Reflect Recent 1‑Year Share Slump Accurately - Yahoo Finance

Mar 10, 2026

How Recursion’s AI Proof of Concept and Equity Raise Will Impact Recursion Pharmaceuticals (RXRX) Investors - Yahoo Finance

Mar 10, 2026

A Look At Recursion Pharmaceuticals (RXRX) Valuation After AI Milestone And Improved Quarterly Results - Yahoo Finance

Mar 10, 2026

Mar 09, 2026

Recursion’s First AI Clinical Proof Links Pipeline Progress With Valuation Gap - Yahoo Finance

Mar 09, 2026

What Makes Recursion Pharmaceuticals (RXRX) So Attractive - Finviz

Mar 09, 2026

Recursion rises on new data for asset for polyps - MSN

Mar 09, 2026

Najat Khan sells 124,403 Recursion Pharmaceuticals (NASDAQ: RXRX) shares - Stock Titan

Mar 09, 2026

Mar 08, 2026

Can This AI Stock Bounce Back in 2026? - Yahoo Finance

Mar 08, 2026

Mar 07, 2026

Day Trade: Why retail investors pile into Recursion Pharmaceuticals Inc. stockTrade Analysis Summary & Community Supported Trade Ideas - Naître et grandir

Mar 07, 2026

Recursion Pharmaceuticals Acquires Full Rights to REV102, Potential Oral Therapy for Rare Bone Disorder Hypophosphatasia - MSN

Mar 06, 2026

BoFA Lowers PT on Recursion Pharmaceuticals (RXRX), Keeps a Hold Rating - Insider Monkey

Mar 06, 2026

Assessing Recursion Pharmaceuticals (RXRX) Valuation After Earnings Jump And New Equity Offering Plans - Sahm

Mar 06, 2026

Mar 05, 2026

ARK Investment Management LLC Purchases 556,868 Shares of Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat

Mar 05, 2026